MRVI CEO reports share buys at $3.24 and $3.21

Maravai LifeSciences Holdings (MRVI) reported insider purchases on Form 4 by CEO and Director Bernd Brust.

Rhea-AI Filing Summary

Maravai LifeSciences Holdings (MRVI) reported insider purchases on Form 4 by CEO and Director Bernd Brust. The filing shows two open‑market buys of Class A common stock: 157,201 shares on 11/11/2025 at a weighted average price of $3.24 and 93,358 shares on 11/12/2025 at a weighted average price of $3.21, executed through The Bernd Brust Management Trust.

Following these transactions, the table lists 250,559 shares indirectly owned via the trust and 2,000,000 shares directly owned. Prices reflect weighted averages across multiple trades within the disclosed ranges.

Insider Trade Summary

Net Buyer: 250,559 shares

Net Buy 3 txns

Insider Brust Bernd

Role Chief Executive Officer

Bought 250,559 shs ($809K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	93,358	$3.21	$300K
Purchase	Class A Common Stock	157,201	$3.24	$509K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 250,559 shares (Indirect, The Bernd Brust Management Trust); Class A Common Stock — 2,000,000 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.18 to $3.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.175 to $3.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MRVI's CEO report buying on Form 4?

Two purchases of Class A common stock: 157,201 shares on 11/11/2025 and 93,358 shares on 11/12/2025.

At what prices were the MRVI shares purchased?

Weighted average prices of $3.24 (range $3.18–$3.25) and $3.21 (range $3.175–$3.25).

Who is the reporting person in the MRVI Form 4?

Bernd Brust, Chief Executive Officer and Director.

How many MRVI shares are listed as indirectly owned after the transactions?

250,559 shares via The Bernd Brust Management Trust.

Does the Form 4 show any direct ownership by the reporting person?

Yes, the table lists 2,000,000 shares as directly owned.

What do the weighted average prices mean in this Form 4?

Shares were bought in multiple trades within stated ranges; the filer will provide detailed breakdowns upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brust Bernd

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/11/2025		P		157,201	A	$3.24(1)	157,201	I	The Bernd Brust Management Trust
Class A Common Stock	11/12/2025		P		93,358	A	$3.21(2)	250,559	I	The Bernd Brust Management Trust
Class A Common Stock								2,000,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.18 to $3.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.175 to $3.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Bernd Brust	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.